| A Phase II Clinical Study of SYH2068 Injection in Adults With Elevated Lipoprotein(a) (NCT07640217) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2026-07-30 |
| A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia (NCT07695597) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2026-07-15 |
| A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant Hypertension (NCT07635914) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2026-05-31 |
| Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial Hypercholesterolemia (NCT07591298) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2026-05-24 |
| Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia. (NCT07547384) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2026-04-05 |
| A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) (NCT07465263) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2026-03-31 |
| A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy (NCT07421284) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2026-03-31 |
| A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia (NCT07421297) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2026-02-28 |
| A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2061 (NCT07241910) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2025-12-23 |
| A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2070 Injection (NCT07241923) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2025-11-15 |
| Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients (NCT07096869) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2025-06-26 |
| Study of SYH2062 Injection in Healthy Chinese Volunteers (NCT06842537) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2025-03-01 |
| A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia (NCT07421232) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2024-12-03 |
| Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting (NCT06543966) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2024-10-28 |
| A Bioequivalence Study of PP3M in Patients With Schizophrenia (NCT07493551) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2024-10-09 |
| A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053 (NCT06229548) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2024-01-08 |
| A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia (NCT06182592) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2024-01-01 |
| Bioequivalence Study of Long-Acting Paliperidone Palmitate in Patients With Schizophrenia (NCT07268430) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2023-12-18 |
| A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection (NCT05801835) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2023-08-25 |
| Bioequivalence of Amphotericin B Liposome for Injection (NCT05913921) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2023-06-02 |
| A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency (NCT05783557) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2023-05-01 |
| Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment (NCT05717764) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2023-02-01 |
| Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) (NCT05551598) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2022-11-28 |
| A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis (NCT05496894) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2022-08-01 |
| Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM (NCT05052970) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2021-10-20 |
| Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients (NCT04920500) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2020-09-04 |
| A Pilot Bioequivalence Study Between Amphotericin B Liposome for Injection and AmBisome® in Healthy Subjects (NCT04993222) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2020-06-04 |